© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 4, 284-292,
February 21, 2001
© 2001 Oxford University Press
Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine
Affiliations of authors: C. D. Harro, M. J. Reynolds, T. C. Mast, R. A. Karron (Center for Immunization Research, Department of International Medicine, School of Hygiene and Public Health), R. B. S. Roden (Department of Pathology, School of Medicine), The Johns Hopkins University, Baltimore, MD; Y.-Y. S. Pang, J. T. Schiller, D. R. Lowy (Laboratory of Cellular Oncology, Division of Basic Sciences), A. Hildesheim (Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics), National Cancer Institute, Bethesda, MD; Z. Wang, J. Dillner, Microbiology and Tumor Biology Centre, Karolinska Institute, Stockholm, Sweden; R. Robinson, Novavax, Inc., Columbia, MD; B. R. Murphy, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda.
Correspondence to: Douglas R. Lowy, M.D., National Institutes of Health, Bldg. 36, Rm. 1D-32, Bethesda, MD 20892 (e-mail: drl{at}helix.nih.gov).
Background: Studies in animal models have shown that systemic immunization with a papillomavirus virus-like particle (VLP) vaccine composed of L1, a major structural viral protein, can confer protection against subsequent experimental challenge with the homologous virus. Here we report results of a double-blind, placebo-controlled, dose-escalation trial to evaluate the safety and immunogenicity of a human papillomavirus (HPV) type 16 (HPV16) L1 VLP vaccine in healthy adults. Methods: Volunteers were given intramuscular injections with placebo or with 10- or 50-µg doses of HPV16 L1 VLP vaccine given without adjuvant or with alum or MF59 as adjuvants at 0, 1, and 4 months. All vaccine recipients were monitored for clinical signs and symptoms for 7 days after each inoculation. Immune responses were measured by an HPV16 L1 VLP-based enzyme-linked immunosorbent assay (ELISA) and by an HPV16 pseudovirion neutralization assay. The antibody titers were given as the reciprocals of the highest dilution showing positive reactivity in each assay. All statistical tests were two-sided. Results: The prevaccination geometric mean ELISA titer for six seropositive individuals was 202 (range, 40–640). All vaccine formulations were well tolerated, and all subjects receiving vaccine seroconverted. Serum antibody responses at 1 month after the third injection were dose dependent in recipients of vaccine without adjuvant or with MF59 but were similar at both doses when alum was the adjuvant. With the higher dose, the geometric means of serum ELISA antibody titers (95% confidence intervals) to purified VLP 1 month after the third injection were as follows: 10 240 (1499 to 69 938) without adjuvant, 10 240 (1114 to 94 145) with MF59, and 2190 (838 to 5723) with alum. Responses of subjects within each group were similar. Neutralizing and ELISA antibody titers were highly correlated (Spearman correlation = .85), confirming that ELISA titers are valid proxies for neutralizing antibodies. Conclusions: The HPV16 L1 VLP vaccine is well tolerated and is highly immunogenic even without adjuvant, with the majority of the recipients achieving serum antibody titers that were approximately 40-fold higher than what is observed in natural infection.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. J. Kemp, A. Hildesheim, R. T. Falk, J. T. Schiller, D. R. Lowy, A. C. Rodriguez, and L. A. Pinto Evaluation of Two Types of Sponges Used To Collect Cervical Secretions and Assessment of Antibody Extraction Protocols for Recovery of Neutralizing Anti-Human Papillomavirus Type 16 Antibodies Clin. Vaccine Immunol., January 1, 2008; 15(1): 60 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Heim, G. Hudelist, A. Geier, H. Szedenik, N. D. Christensen, N. Concin, A. Bergant, B. Volgger, K. Czerwenka, and R. Hopfl Type-Specific Antiviral Antibodies to Genital Human Papillomavirus Types in Mothers and Newborns Reproductive Sciences, December 1, 2007; 14(8): 806 - 814. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Bishop, J. Dasgupta, M. Klein, R. L. Garcea, N. D. Christensen, R. Zhao, and X. S. Chen Crystal Structures of Four Types of Human Papillomavirus L1 Capsid Proteins: UNDERSTANDING THE SPECIFICITY OF NEUTRALIZING MONOCLONAL ANTIBODIES J. Biol. Chem., October 26, 2007; 282(43): 31803 - 31811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fraillery, D. Baud, S. Y.-Y. Pang, J. Schiller, M. Bobst, N. Zosso, F. Ponci, and D. Nardelli-Haefliger Salmonella enterica Serovar Typhi Ty21a Expressing Human Papillomavirus Type 16 L1 as a Potential Live Vaccine against Cervical Cancer and Typhoid Fever Clin. Vaccine Immunol., October 1, 2007; 14(10): 1285 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stanley Prophylactic HPV vaccines J. Clin. Pathol., September 1, 2007; 60(9): 961 - 965. [Full Text] [PDF]
|
|
|
|
|
|
A. Garcia-Pineres, A. Hildesheim, L. Dodd, T. J. Kemp, M. Williams, C. Harro, D. R. Lowy, J. T. Schiller, and L. A. Pinto Cytokine and Chemokine Profiles following Vaccination with Human Papillomavirus Type 16 L1 Virus-Like Particles Clin. Vaccine Immunol., August 1, 2007; 14(8): 984 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Chan and J. S. Berek Impact of the Human Papilloma Vaccine on Cervical Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2975 - 2982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Da Silva, S. C. Fausch, J. S. Verbeek, and W. M. Kast Uptake of Human Papillomavirus Virus-Like Particles by Dendritic Cells Is Mediated by Fc{gamma} Receptors and Contributes to Acquisition of T Cell Immunity J. Immunol., June 15, 2007; 178(12): 7587 - 7597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-S. Quan, C. Huang, R. W. Compans, and S.-M. Kang Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus J. Virol., April 1, 2007; 81(7): 3514 - 3524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fontaine, C. Mascaux, C. Weyn, A. Bernis, N. Celio, P. Lefevre, L. Kaufman, and C. Garbar Evaluation of Combined General Primer-Mediated PCR Sequencing and Type-Specific PCR Strategies for Determination of Human Papillomavirus Genotypes in Cervical Cell Specimens J. Clin. Microbiol., March 1, 2007; 45(3): 928 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Fakruddin, R. A. Lempicki, R. J. Gorelick, J. Yang, J. W. Adelsberger, A. J. Garcia-Pineres, L. A. Pinto, H. C. Lane, and T. Imamichi Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27 Blood, March 1, 2007; 109(5): 1841 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hervas-Stubbs, P. Rueda, L. Lopez, and C. Leclerc Insect Baculoviruses Strongly Potentiate Adaptive Immune Responses by Inducing Type I IFN J. Immunol., February 15, 2007; 178(4): 2361 - 2369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Skountzou, F.-S. Quan, S. Gangadhara, L. Ye, A. Vzorov, P. Selvaraj, J. Jacob, R. W. Compans, and S.-M. Kang Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- Macrophage Colony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles J. Virol., February 1, 2007; 81(3): 1083 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Schiller and D. R. Lowy Prospects for Cervical Cancer Prevention by Human Papillomavirus Vaccination Cancer Res., November 1, 2006; 66(21): 10229 - 10232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zamora, A. Handisurya, S. Shafti-Keramat, D. Borchelt, G. Rudow, K. Conant, C. Cox, J. C. Troncoso, and R. Kirnbauer Papillomavirus-Like Particles Are an Effective Platform for Amyloid-beta Immunization in Rabbits and Transgenic Mice J. Immunol., August 15, 2006; 177(4): 2662 - 2670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R Schmiedeskamp and D. R Kockler Human Papillomavirus Vaccines Ann. Pharmacother., July 1, 2006; 40(7): 1344 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Pichichero Prevention of Cervical Cancer Through Vaccination of Adolescents Clinical Pediatrics, June 1, 2006; 45(5): 393 - 398. [PDF]
|
|
|
|
|
|
D. Kuck, T. Lau, B. Leuchs, A. Kern, M. Muller, L. Gissmann, and J. A. Kleinschmidt Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1 J. Virol., March 15, 2006; 80(6): 2621 - 2630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Ko, K.-S. Choi, J.-J. Nah, D. J. Paton, J.-K. Oem, G. Wilsden, S.-Y. Kang, N.-I. Jo, J.-H. Lee, J.-H. Kim, et al. Noninfectious Virus-Like Particle Antigen for Detection of Swine Vesicular Disease Virus Antibodies in Pigs by Enzyme-Linked Immunosorbent Assay Clin. Vaccine Immunol., August 1, 2005; 12(8): 922 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Orozco, J. J. Carter, L. A. Koutsky, and D. A. Galloway Humoral Immune Response Recognizes a Complex Set of Epitopes on Human Papillomavirus Type 6 L1 Capsomers J. Virol., August 1, 2005; 79(15): 9503 - 9514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Warfield, G. Olinger, E. M. Deal, D. L. Swenson, M. Bailey, D. L. Negley, M. K. Hart, and S. Bavari Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection J. Immunol., July 15, 2005; 175(2): 1184 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Yang, C. M. Wheeler, X. Chen, S. Uematsu, K. Takeda, S. Akira, D. V. Pastrana, R. P. Viscidi, and R. B. S. Roden Papillomavirus Capsid Mutation To Escape Dendritic Cell-Dependent Innate Immunity in Cervical Cancer J. Virol., June 1, 2005; 79(11): 6741 - 6750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bousarghin, P. Hubert, E. Franzen, N. Jacobs, J. Boniver, and P. Delvenne Human papillomavirus 16 virus-like particles use heparan sulfates to bind dendritic cells and colocalize with langerin in Langerhans cells J. Gen. Virol., May 1, 2005; 86(5): 1297 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berg, J. DiFatta, E. Hoiczyk, R. Schlegel, and G. Ketner Viable adenovirus vaccine prototypes: High-level production of a papillomavirus capsid antigen from the major late transcriptional unit PNAS, March 22, 2005; 102(12): 4590 - 4595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Buck, C. D. Thompson, Y.-Y. S. Pang, D. R. Lowy, and J. T. Schiller Maturation of Papillomavirus Capsids J. Virol., March 1, 2005; 79(5): 2839 - 2846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Viscidi, B. Snyder, S. Cu-Uvin, J. W. Hogan, B. Clayman, R. S. Klein, J. Sobel, and K. V. Shah Human Papillomavirus Capsid Antibody Response to Natural Infection and Risk of Subsequent HPV Infection in HIV-Positive and HIV-Negative Women Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 283 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Yang, F. M. Murillo, H. Cui, R. Blosser, S. Uematsu, K. Takeda, S. Akira, R. P. Viscidi, and R. B. S. Roden Papillomavirus-Like Particles Stimulate Murine Bone Marrow-Derived Dendritic Cells To Produce Alpha Interferon and Th1 Immune Responses via MyD88 J. Virol., October 15, 2004; 78(20): 11152 - 11160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, R. Fayad, X. Wang, D. Quinn, and L. Qiao Human Immunodeficiency Virus Type 1 Gag-Specific Mucosal Immunity after Oral Immunization with Papillomavirus Pseudoviruses Encoding Gag J. Virol., October 1, 2004; 78(19): 10249 - 10257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Yang, F. M. Murillo, K.-Y. Lin, W. H. Yutzy IV, S. Uematsu, K. Takeda, S. Akira, R. P. Viscidi, and R. B. S. Roden Human Papillomavirus Type-16 Virus-Like Particles Activate Complementary Defense Responses in Key Dendritic Cell Subpopulations J. Immunol., August 15, 2004; 173(4): 2624 - 2631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Lowy, D. Nardelli-Haefliger, A. Hildesheim, and J. T. Schiller RESPONSE: Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles J Natl Cancer Inst, March 3, 2004; 96(5): 413 - 414. [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, A.-C. Rodriguez, F. P. Bowman, R. Herrero, M. Schiffman, M. C. Bratti, L. A. Morera, D. Schust, P. Crowley-Nowick, and A. Hildesheim Comparison of Ophthalmic Sponges for Measurements of Immune Markers from Cervical Secretions Clin. Vaccine Immunol., March 1, 2004; 11(2): 399 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Baud, J. Benyacoub, V. Revaz, M. Kok, F. Ponci, M. Bobst, R. Curtiss III, P. De Grandi, and D. Nardelli-Haefliger Immunogenicity against Human Papillomavirus Type 16 Virus-Like Particles Is Strongly Enhanced by the PhoPc Phenotype in Salmonella enterica Serovar Typhimurium Infect. Immun., February 1, 2004; 72(2): 750 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Viscidi, M. Schiffman, A. Hildesheim, R. Herrero, P. E. Castle, M. C. Bratti, A. C. Rodriguez, M. E. Sherman, S. Wang, B. Clayman, et al. Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection: Results from a Population-Based Study in Costa Rica Cancer Epidemiol. Biomarkers Prev., February 1, 2004; 13(2): 324 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mandic and T. Vujkov Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann. Onc., February 1, 2004; 15(2): 197 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Y. F. Ho, Y. Y. Studentsov, R. Bierman, and R. D. Burk Natural History of Human Papillomavirus Type 16 Virus-Like Particle Antibodies in Young Women Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 110 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shafti-Keramat, A. Handisurya, E. Kriehuber, G. Meneguzzi, K. Slupetzky, and R. Kirnbauer Different Heparan Sulfate Proteoglycans Serve as Cellular Receptors for Human Papillomaviruses J. Virol., December 15, 2003; 77(24): 13125 - 13135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Rousseau, M. Abrahamowicz, L. L. Villa, M. C. Costa, T. E. Rohan, and E. L. Franco Predictors of Cervical Coinfection with Multiple Human Papillomavirus Types Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1029 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-T. Le and A. J. Giaccia Therapeutic Exploitation of the Physiological and Molecular Genetic Alterations in Head and Neck Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4287 - 4295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Devaraj, M. L. Gillison, and T.-C. Wu DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA Crit. Rev. Oral. Biol. Med., September 1, 2003; 14(5): 345 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Warzecha, H. S. Mason, C. Lane, A. Tryggvesson, E. Rybicki, A.-L. Williamson, J. D. Clements, and R. C. Rose Oral Immunogenicity of Human Papillomavirus-Like Particles Expressed in Potato J. Virol., August 15, 2003; 77(16): 8702 - 8711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nardelli-Haefliger, D. Wirthner, J. T. Schiller, D. R. Lowy, A. Hildesheim, F. Ponci, and P. De Grandi Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles J Natl Cancer Inst, August 6, 2003; 95(15): 1128 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Varsani, A.-L. Williamson, D. de Villiers, I. Becker, N. D. Christensen, and E. P. Rybicki Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16 J. Virol., August 1, 2003; 77(15): 8386 - 8393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T W Reid and N Dushku Does human papillomavirus cause pterygium? Br. J. Ophthalmol., July 1, 2003; 87(7): 806 - 808. [Full Text] [PDF]
|
|
|
|
|
|
X.-M. Wang, J. C. Cook, J. C. Lee, K. U. Jansen, N. D. Christensen, S. W. Ludmerer, and W. L. McClements Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes J. Gen. Virol., June 1, 2003; 84(6): 1493 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Parmiani, L. Pilla, C. Castelli, and L. Rivoltini Vaccination of patients with solid tumours Ann. Onc., June 1, 2003; 14(6): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Lowy and I. H. Frazer Chapter 16: Prophylactic Human Papillomavirus Vaccines J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 111 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Crum, D. W. Abbott, and B. J. Quade Cervical Cancer Screening: From the Papanicolaou Smear to the Vaccine Era J. Clin. Oncol., May 15, 2003; 21(90100): 224s - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ohlschlager, W. Osen, K. Dell, S. Faath, R. L. Garcea, I. Jochmus, M. Muller, M. Pawlita, K. Schafer, P. Sehr, et al. Human Papillomavirus Type 16 L1 Capsomeres Induce L1-Specific Cytotoxic T Lymphocytes and Tumor Regression in C57BL/6 Mice J. Virol., April 15, 2003; 77(8): 4635 - 4645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Finnen, K. D. Erickson, X. S. Chen, and R. L. Garcea Interactions between Papillomavirus L1 and L2 Capsid Proteins J. Virol., April 15, 2003; 77(8): 4818 - 4826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Schiffman and P. Castle Epidemiologic Studies of a Necessary Causal Risk Factor: Human Papillomavirus Infection and Cervical Neoplasia J Natl Cancer Inst, March 19, 2003; 95(6): E2 - E2. [Full Text]
|
|
|
|
 |
|
 E. M. Burd Human Papillomavirus and Cervical Cancer Clin. Microbiol. Rev., January 1, 2003; 16(1): 1 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chackerian, P. Lenz, D. R. Lowy, and J. T. Schiller Determinants of Autoantibody Induction by Conjugated Papillomavirus Virus-Like Particles J. Immunol., December 1, 2002; 169(11): 6120 - 6126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Koutsky, K. A. Ault, C. M. Wheeler, D. R. Brown, E. Barr, F. B. Alvarez, L. M. Chiacchierini, K. U. Jansen, and the Proof of Principle Study Investigators A Controlled Trial of a Human Papillomavirus Type 16 Vaccine N. Engl. J. Med., November 21, 2002; 347(21): 1645 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Crum The Beginning of the End for Cervical Cancer? N. Engl. J. Med., November 21, 2002; 347(21): 1703 - 1705. [Full Text] [PDF]
|
|
|
|
|
|
P. Greenwald Cancer Prevention Clinical Trials J. Clin. Oncol., September 15, 2002; 20(90001): 14s - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Steller Cervical Cancer Vaccines: Progress and Prospects Reproductive Sciences, September 1, 2002; 9(5): 254 - 264. [Abstract] [PDF]
|
|
|
|
|
|
M. E. Embers, L. R. Budgeon, M. Pickel, and N. D. Christensen Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein J. Virol., August 28, 2002; 76(19): 9798 - 9805. [Abstract] [Full Text] [PDF]
|
|